Related Experiment Video
Updated: Dec 25, 2025
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Aspirin for Primary Prevention of Coronary Artery Disease
Insights
Aspirin for primary prevention of coronary artery disease (CAD) may cause more harm than benefit due to increased bleeding risk, despite reducing non-fatal heart attacks and strokes. Current guidelines reflect this shift in practice.
Area of Science:
- Cardiology
- Preventive Medicine
- Clinical Trials
Background:
- Coronary artery disease (CAD) prevention is crucial for reducing disease burden.
- Aspirin was a long-standing primary prevention strategy for CAD.
- Recent trials (ARRIVE, ASCEND, ASPREE) challenge aspirin's routine use.
Purpose of the Study:
- To review current evidence on aspirin for primary CAD prevention.
- To analyze recent clinical trial data contrasting with older findings.
- To highlight updated guidelines from major cardiology societies.
Main Methods:
- Review of landmark clinical trials (ARRIVE, ASCEND, ASPREE).
- Analysis of comparative effectiveness of aspirin versus placebo.
- Examination of bleeding risk versus cardiovascular event reduction.
- Synthesis of current European Society of Cardiology (ESC), American College of Cardiology (ACC), and American Heart Association (AHA) guidelines.
Main Results:
- Aspirin use in primary prevention showed a reduction in non-fatal myocardial infarction (MI) and stroke.
- However, these benefits were offset by a significantly higher risk of bleeding events.
- Contemporary CAD risk management includes lifestyle changes and statins, altering the risk-benefit profile of aspirin.
Conclusions:
- The routine prescription of aspirin for primary prevention of CAD is increasingly questioned.
- The balance of benefits versus harms suggests aspirin may be more detrimental than beneficial in the current era.
- Updated clinical guidelines from major cardiovascular societies reflect a more cautious approach to aspirin use for primary prevention.
Abstract:
Primary prevention of coronary artery disease (CAD) is an important means to reduce the burden of the disease. Aspirin has been widely prescribed over the last several decades as part of primary CAD prevention strategy. However, 3 recent hallmark trials - ARRIVE, ASCEND and ASPREE have raised serious questions about this common practice. Although, aspirin reduced incidence of non-fatal MI and stroke in these recent studies, bleeding risk was higher. In the present era, where regular exercise, healthy diet, smoking cessation, and statins are used to manage the risk factors of CAD, additional prescription of aspirin seems more harmful than beneficial. The guidelines of major societies such as European Society of Cardiology (ESC), American College of Cardiology (ACC), and American Heart Association (AHA) also reflect this shift. In this article, the authors aim to highlight the current evidence on aspirin use for primary prevention of CAD, in the context of evolving contrasting clinical trial data from the last 2 decades. We also highlight the pertinent sections of the most recent clinical guidelines of European Society of Cardiology, American College of Cardiology, and American Heart Association in this article.
More Related Videos
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
01:26Coronary Artery Disease IV: Preventive Measures
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Atherosclerosis III: Management
01:27Peripheral Artery Disease III: Interprofessional Care
01:26Angina IV: Management